Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q3 2024 Earnings Presentation
27 slides from Expres2ion Biotech Holding Ab's earnings presentation, Nov 14, 2024
Slide 1: ExpreS2ion Biotech Q3 2024 Earnings Presentation
healthier world Hosted by & HH ANDERSEN ExpreS2ion Biotech Holding AB CAPITAL Org, Nr. $59033-3729
Slide 2: Agenda
expreSeion BIOTECH Agenda * Management discussion & analysis Financial results Corporate actions * Q&SA
Slide 3: Management discussion & analysis
discussion & analysis
Slide 4: Major news since Q2
expreSeion BIOTECH Major news since Q2 Gross proceeds from rights issue of MSEK 30 U.S. patent issued Filed CTA + Key milestone in pipeline progression for ES2B-C001 Updated ve onaing + To clarify our value proposition to customers, partners and investors Sll term sheet + For development and commerc
Slide 5: Vaccine pipeline
Vaccine pipeline Programs that are controlled or semi-controlled by ExpreS2ion expreSceion BIOTECH Discovery Lead opt CTA-enabling Phi Ph2 Ph3. Market size CTA submission August 2024 ES2B-CO001 >€10 HER2+ breast cancer Oncology aTPereil = Billion’ (therapeutic) Preclinical data 09 November 2024 be e
Slide 6: ExpreS2 platform proof-of-concept
ExpreS2 platform proof-of-concept Phase III validated + numerous additional pharmaceutica oe) Influenza MucoVax influenza wiles VICI Nipah Undisclosed projects ES2B-1002 cytomegalovirus Influenza INDIGO influenza x ES2B-CO001 HER2 breast cancer expreSceion BIOTECH and biotech company protein project
Slide 7: ES2B-C001 - a breakthrough BC vaccine
expreSeion ES2B-CO01 - a breakthrough BC vaccine “me Based on technology with clinical PoC and Phase III validation (COVID-19) HER2 protein (all 4 extra-cellular sub domains) ExpreS2”™ platform Secure & high-density display of HER2 in cVLP (180 attachment sites) AdaptVac's VLP technology HERCEPTIN™
Slide 8: ES2B-C001 update
ES2B-CO01 update As planned, on path towards first-in-human clinical Phase | trial with HER2-VLP Submission of Phase 1CTA on 6" August RFI= Request for Information Validation Ensure the application is complete and meets all regulatory requirements. Status: Completed 2 September 2024. Scientific and
Slide 9: First-in-human Phase I clinical trial
First-in-human Phase | clinical trial Clinical study (ES2B-C001-S1) protocol title A first-in-human phase |, open-label, dose- escalating trial to assess the safety, tolerability and immunogenicity / preliminary antitumor activity of ES2B-COO1, with or without Montanide, in HER2 expressing metastati
Slide 10: Malaria Vaccines - so far thru Univ. of Oxford
expreScion BIOTECH Malaria Vaccines — so far thru Univ. of Oxford 4 vaccine candidates under development, progressing and sponsored through Univ. of Oxford Malaria Vaccine (Target) Partners 7 studies on-going and planned Clinical INK Intervention/treatment * 2023 2024 2025 2026 Site Blood stage (RH5
Slide 11: Malaria Vaccines - Now with SIIPL interest
expreSeion BIOTECH Malaria Vaccines — Now with SIIPL interest! 4 vaccine candidates under development, progressing and sponsored through Univ. of Oxford Malaria Vaccine (Target) Partners Serum Institute of India Pvt. Limited (“SIIPL") and ExpreS2ion entered in a term sheet on 16% October 2024 “Acces
Slide 12: Upcoming events
expreSeion BIOTECH Upcoming events Opportunities to learn more about specific projects and interact with management 18 November, London * LSX Investival 21 November, Lund * BioStock Life Science Summit 27 November, Stockholm + Analysguiden Stora Aktiedagen 12
Slide 13: Financial results
Financial results
Slide 14: Summary of Q3 2024 and year-to-date results
expreSeion S f 2024 to-dat It _ Q3 2024 Q3 2023 % Change YTD 2024 YTD 2023 % Change Key income statement figures, SEK ‘000s Operating income 1,689 1,856 -9% 5,647 6,515 -13% Profit/loss after financial items -13,010 -23,394 44% -25,210 -85,241 -70% Profit/loss -10,460 -21,826 -52% -20,776 -78,172 -7
Slide 15: Net sales and other operating income
Net sales Other operating income 1Q22 3Q22 1Q23 3Q23 1Q24 3Q24 1Q22 3Q22 1Q23 3Q23 1Q24 3Q24
Slide 16: Operating costs
Operating costs SEK ‘000s expreSeion 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 BIOTECH -38% 1Q24 2Q24 3Q24 16
Slide 17: -10,000 -20,000 -30,000 -40,000
0 -10,000 -20,000 -30,000 -40,000
Slide 18: Profit / loss for the period
Profit / loss for the period SEK ‘000s 3Q profit / loss ° | -30,000 =21,826 -60,000 -90,000 -120,000 -150,000 2023 2024 expreSeion BIOTECH Year-to-date profit / loss , LJ -25,000 -20,776 -50,000 -73% -75,000 -78,172 -100,000 2023 2024 18
Slide 19: Cash development, first nine months of 24
expreSeion BIOTECH Cash development, first nine months of 2024 SEK millions 90.0 80.0 26.L T64 -0.6 70.0 60.0 57.6 50.0 21.2 Rights Issue 40.0 30.0 -28.4 AdaptVac Dividend 20.0 10.0 0.0 December 2023 Operations Investing Financing FX September 2024 19
Slide 20: 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24
168 150 125 111 88 77 76 72 69 58 60 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24
Slide 21: Corporate actions
Corporate actions
Slide 22: Reverse share split
expreScion BIOTECH Reverse share split Psychological Institutional investor limitation Upcoming Euroclear changes Immaterial cost Nothing 22
Slide 23: TO warrants
expreScion TO 10 warrants _ Subscription period commences on November 20, 2024 ~ * Nov 20 - Dec 4, 2024 - 4O warrants : 1 share - 70% of November 1-14 . . . volume-weighted average + Exercise early, broker + Adjusted for reverse split price windows may be shorter + Subject to SEK 60.00 cap and SEK 4
Slide 24: Looking forward
Looking forward ExpreS2ion is progressing towards significant milestones ESZBCOORCTA decision ES2B-COO!1 Phase | initiation Extensions of IP protection Further validation of platform technologies though grant- sponsored projects expreScion BIOTECH 24
Slide 25: Q&A
Slide 26: Disclaimer
expreScion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentati
Slide 27: Investor Relations
Investor Relations
ExpreS2ion Biotech Holding — Q3 2024 Earnings Presentation on 6ix